Journal
VACCINE
Volume 27, Issue 42, Pages 5885-5895Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2009.07.039
Keywords
MVA; HIV vaccine; Immune response
Categories
Funding
- Intramural Research Program
- National Institute of Allergy and Infectious Diseases
- U.S. Army Medical Research and Materiel Command [DAMD17-98-27007]
Ask authors/readers for more resources
Recombinant modified vaccinia virus Ankara (rMVA) expressing HIV-1 genes are promising vaccine candidates. Toward the goal of conducting clinical trials with one or a cocktail of recombinant viruses, four rMVAs expressing env and gag-pol genes from primary HIV-1 isolates representing predominant subtypes from Kenya, Tanzania, Uganda, and Thailand (A, C, D, and CRF01_AE, respectively) were constructed. Efficient expression, processing, and function of Env and Gag were demonstrated. All inserted genes were shown to be genetically stable after repeated passage in cell culture. Strong HIV-specific cellular and humoral immune responses were elicited in mice immunized with each individual vaccine candidate. The MVA/CMDR vaccine candidate expressing CRF01_AE genes has elicited HIV-specific T-cell responses in two independent Phase I clinical trials. Further testing of the other rMVA is warranted. Published by Elsevier Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available